ISIS Pharmaceuticals (ISIS -1.8%) and Genzyme (SNY) say the Committee for Medicinal Products for...

|By:, SA News Editor

ISIS Pharmaceuticals (ISIS -1.8%) and Genzyme (SNY) say the Committee for Medicinal Products for Human Use adopted a negative opinion for its marketing authorization of the cholesterol drug Kynamro, a setback for the treatment.